vadimezan has been researched along with Animal Mammary Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Altan-Bonnet, G; Bercovici, N; Bismuth, G; Donnadieu, E; Feuillet, V; Finisguerra, V; Guerin, MV; Guilbert, T; Regnier, F; Thoreau, M; Trautmann, A; Vimeux, L; Weiss, JM | 1 |
| Bang, S; Donnelly, CR; Hilton, MJ; Ji, RR; Jiang, C; Lee, M; Liao, Y; Luo, X; McGinnis, A; Tao, X; Wang, K | 1 |
| Breidahl, T; Horsman, MR; Maxwell, RJ; Nielsen, FU; Stødkilde-Jørgensen, H | 1 |
3 other study(ies) available for vadimezan and Animal Mammary Carcinoma
| Article | Year |
|---|---|
TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors.
Topics: Animals; Female; Interferon Regulatory Factor-3; Interferon-alpha; Interferon-beta; Macrophages; Mammary Neoplasms, Animal; Mammary Tumor Virus, Mouse; Mice; Phosphorylation; Transforming Growth Factor beta; Xanthones | 2019 |
STING suppresses bone cancer pain via immune and neuronal modulation.
Topics: Analgesics; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Female; Femur; Ganglia, Spinal; Homeodomain Proteins; Hyperalgesia; Interferons; Male; Mammary Neoplasms, Animal; Membrane Proteins; Mice, Inbred C57BL; Neoplasm Metastasis; Neurons; Nociception; Osteoclasts; Osteogenesis; Receptor, Interferon alpha-beta; Signal Transduction; Tumor Burden; Tumor Microenvironment; Xanthones | 2021 |
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Female; Hydrogen-Ion Concentration; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Nucleosides; Organophosphorus Compounds; Phosphates; Stilbenes; Time Factors; Treatment Outcome; Xanthones | 2006 |